Search | Syneos Health Communications

#1

The growing appeal of orphan drugs to manufacturers isn’t a groundbreaking story, but a new report identifies some head-spinning facts behind the focal shift from blockbuster to rare-disease drugs.

#2

The State Supreme Court just resolved a 10-year battle between the Cleveland Clinic and a former patient, retired U.S.

#3

Complications from drug interactions can present patients with whole new afflictions.

#4

A landmark approval by the FDA will put the first marijuana-derived prescription drug behind pharmacy counters this fall.

#5

Holistic healthcare brand Otsuka Pharmaceutical has announced a promising partnership with Science 37, the trailblazing startup out of MIT that’s transforming clinical trials for everyone.

#6

Nonprofit hospital system Partners HealthCare has unveiled a joint venture with Circulation, an on-demand rideshare service, through which Medicare patients receive free rides to their doctor’s offices in non-emergencies.

#7

Nestlé, the brand you might associate first with such decadent confections as Crunch bars, Laffy Taffy, and Toll House cookies, has made a decided turn toward the healthful.

#8

With funding from Google, Stanford, and venture capital giants Sequoia and Andreessen Horowitz, seven-year-old Zipline has already revolutionized health care in Rwanda.

#9

Advantia Health, a leading-edge medical company committed to empowering women with integrated health care services, announced a new partnership with Elligo Health Research, which will offer Advantia’s clients access to a whole new realm of resources, through clinical trials.

#10

Digital therapeutics, or DTx, are distinct from digital health products, and are driven by software programs that can be prescribed to prevent, manage, or treat a medical disorder or disease, as stated by the Digital Therapeutics Alliance.

#11

A new Deloitte report explores the near-future of blockchain: how seriously the world’s top executives, including many in healthcare, regard the emerging technology and how soon they might invest in it.

#12

To retail behemoths, the health care realm is growing irresistible.

#13

A recent proposal by the U.S.

#14

Beginning with its acquisition of PillPack, Amazon’s grand entrance into healthcare continues with its partnership with J.P.

#15

Pfizer and Novartis have been independently developing therapies for nonalcoholic steatohepatitis (NASH), and they’re now set to join forces to yield a combination therapy for the fatty liver disease linked closely with metabolic disorders.

#16

Forecasting next year’s biggest shifts within the healthcare landscape, Syneos Health has released 2019 Health Trend Ten, available for download now, which explicates ten of the trends that will redefine healthcare globally.

#17

After taking some major leaps into healthcare, Google has begun solidifying its foothold in the space by appointing Dr.

#18

Amazon Web Services (AWS) has unveiled new machine-learning tools reflecting—and beginning to tackle—some of the greatest challenges facing modern medicine.

#19

Pharmaceutical giant Roche’s new app for people with multiple sclerosis (MS) revolutionizes how doctors care for patients with the disease.

#20

In some rooms at Cedars-Sinai Hospital, patients won’t spend a moment alone—sort of—now that the leading Beverly Hills medical center has partnered with Aiva Health to make select rooms smart.

#21

Is the market prepared for DTx?

#22

Digital health company Peerwell created an app to prepare patients for surgery and, in turn, reduce the amount of time they spend in the hospital.

#23

GlaxoSmithKline announced that it will acquire Waltham, Massachusetts-based drug company Tesaro, which develops novel cancer treatments, for $5.1 billion cash.

#24

In a telling new study, pre- and post-surgical efforts by pharmacists yielded staggering effects on patient opioid use.

#25

With there being so many different stakeholders, including patients, providers and payers, panelists at the 2019 Digital Medicine & MedTech Showcase pointed to a number of different adoption roadblocks—and successes.

#26

An expert panel that advises U.S. federal regulatory authorities has recommended approval of Esketamine, Johnson & Johnson’s brand-new treatment for depression.

#27

In a new Harvard Business Review article, brand positioning expert Denise Lee Yohn distills some of the most useful marketing points gleaned from her 25 years of marketing leadership.

#28

Not your typical geotag for pharmaceutical innovation, Jackson Hole and its most prominent biologist, Paul Cox, may turn decades’ and billions of dollars’ worth of Alzheimer’s research on its head.

#29

Responding to rampant criticism of rising drug prices, pharma giant Eli Lilly will begin selling an authorized generic of its preeminent insulin therapy, Humalog, at half-price.

#30

Ernest Quintana knew he had long suffered from a deadly lung disease when he was rushed to the hospital, but the news of his imminent death still profoundly shocked him and his family—not because of its grimness but who delivered it: a robot.

Search Results

Connect

Site

Search Results

Newsletter

Connect

Site

Subscribe to our RSS feed